Article: Economic evaluations of immunization programs as an indispensable tool for policymakers

Introducing new vaccines within national immunization programs requires careful consideration of disease- and vaccine-related issues as well as of the strength of the program and the affected health system. Economic evaluations play an essential role in this process. In this editorial, we set the context and invite contributions for a BMC Health Services Research Collection of articles titled 'Economic Evaluations of Vaccine Programs'.

Citing Articles

Impact of twelve immunization-preventable infectious diseases on population health using disability-adjusted life years (DALYs) in Spain.

Perez-Rubio A, Mestre-Ferrandiz J, Lopez-Belmonte J, Diaz-Aguilo A, Lorenzo-Herrero S, Crespo C BMC Infect Dis. 2024; 24(1):779.

PMID: 39103777 PMC: 11299363. DOI: 10.1186/s12879-024-09637-x.

References

1.

Shen A, Farrell M, Vandenbroucke M, Fox E, Pablos-Mendez A . Applying lessons learned from the USAID family planning graduation experience to the GAVI graduation process. Health Policy Plan. 2014; 30(6):687-95. DOI: 10.1093/heapol/czu045. View

2.

Mauskopf J, Blake L, Eiden A, Roberts C, Hu T, Nyaku M . Economic Evaluation of Vaccination Programs: A Guide for Selecting Modeling Approaches. Value Health. 2022; 25(5):810-823. DOI: 10.1016/j.jval.2021.10.017. View

3.

Connolly M, Kotsopoulos N . Estimating the Fiscal Consequences of National Immunization Programs Using a "Government Perspective" Public Economic Framework. Vaccines (Basel). 2020; 8(3). PMC: 7564721. DOI: 10.3390/vaccines8030495. View

4.

Haider S, Chaikledkaew U, Thavorncharoensap M, Youngkong S, Islam M, Thakkinstian A . Systematic Review and Meta-Analysis of Cost-effectiveness of Rotavirus Vaccine in Low-Income and Lower-Middle-Income Countries. Open Forum Infect Dis. 2019; 6(4):ofz117. PMC: 6488528. DOI: 10.1093/ofid/ofz117. View

5.

Verguet S, Olson Z, Babigumira J, Desalegn D, Johansson K, Kruk M . Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis. Lancet Glob Health. 2015; 3(5):e288-96. DOI: 10.1016/S2214-109X(14)70346-8. View

6.

Saadatian-Elahi M, Horstick O, Breiman R, Gessner B, Gubler D, Louis J . Beyond efficacy: The full public health impact of vaccines. Vaccine. 2016; 34(9):1139-47. PMC: 11345718. DOI: 10.1016/j.vaccine.2016.01.021. View

7.

Verguet S, Kim J, Jamison D . Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. Pharmacoeconomics. 2016; 34(9):913-23. PMC: 4980400. DOI: 10.1007/s40273-016-0414-z. View

8.

Shen A, Weiss J, Andrus J, Pecenka C, Atherly D, Taylor K . Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction. Health Aff (Millwood). 2016; 35(2):272-6. DOI: 10.1377/hlthaff.2015.1418. View

9.

Hutubessy R, Lauer J, Giersing B, Sim S, Jit M, Kaslow D . The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making. BMC Med. 2023; 21(1):229. PMC: 10318807. DOI: 10.1186/s12916-023-02929-0. View

10.

Bhutta Z, Sommerfeld J, Lassi Z, Salam R, Das J . Global burden, distribution, and interventions for infectious diseases of poverty. Infect Dis Poverty. 2014; 3:21. PMC: 4126350. DOI: 10.1186/2049-9957-3-21. View

11.

Ozawa S, Mirelman A, Stack M, Walker D, Levine O . Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review. Vaccine. 2012; 31(1):96-108. DOI: 10.1016/j.vaccine.2012.10.103. View

Economic Evaluations of Immunization Programs As an Indispensable Tool for Policymakers